Cargando…
Development, Optimization, and Validation of a High Throughput Screening Assay for Identification of Tat and Type II Secretion Inhibitors of Pseudomonas aeruginosa
Antibiotics are becoming less effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrobial therapies based on the inhibition of specific virulence-related traits, as opposed to growth inhibitors, constitute an innovative and appealing approach to tackle th...
Autores principales: | Massai, Francesco, Saleeb, Michael, Doruk, Tugrul, Elofsson, Mikael, Forsberg, Åke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635566/ https://www.ncbi.nlm.nih.gov/pubmed/31355152 http://dx.doi.org/10.3389/fcimb.2019.00250 |
Ejemplares similares
-
Identification of Small Molecules Blocking the Pseudomonas aeruginosa Type III Secretion System Protein PcrV
por: Sundin, Charlotta, et al.
Publicado: (2021) -
Modulation of the immune response by the Pseudomonas aeruginosa type-III secretion system
por: Jouault, Albane, et al.
Publicado: (2022) -
Glutathione Activates Type III Secretion System Through Vfr in Pseudomonas aeruginosa
por: Zhang, Yani, et al.
Publicado: (2019) -
MvaT binds to the P
(exsC)
promoter to repress the type III secretion system in Pseudomonas aeruginosa
por: Yin, Liwen, et al.
Publicado: (2023) -
Itaconimides as Novel Quorum Sensing Inhibitors of Pseudomonas aeruginosa
por: Fong, July, et al.
Publicado: (2019)